Antecedent Neuroimaging Biomarkers

$44,318P01FY2013AGNIH

Washington University, Saint Louis MO

Investigators

Linked publications & trials

Paper 39689057 Paper 39677464 Paper 39606367 Paper 39559880 Paper 39553251 Paper 39540665 Paper 39484251 Paper 39483923 Paper 39444005 Paper 39417134 Paper 39412405 Paper 39385241 Paper 39371140 Paper 39351959 Paper 39314357 Paper 39279994 Paper 39177169 Paper 39165480 Paper 39148846 Paper 39147830 Paper 39108475 Paper 39077866 Paper 39041391 Paper 39020361 Paper 39011113 Paper 39010871 Paper 39006421 Paper 38970402 Paper 38963256 Paper 38958563 Paper 38958117 Paper 38956096 Paper 38947090 Paper 38947044 Paper 38947004 Paper 38923730 Paper 38903124 Paper 38888066 Paper 38883718 Paper 38823362 Paper 38788065 Paper 38776513 Paper 38712163 Paper 38712073 Paper 38687811 Paper 38683905 Paper 38666355 Paper 38602816 Paper 38559166 Paper 38554257 Paper 38526701 Paper 38514824 Paper 38496633 Paper 38463962 Paper 38445545 Paper 38410465 Paper 38400792 Paper 38395947 Paper 38382645 Paper 38379519 Paper 38365585 Paper 38355735 Paper 38353984 Paper 38315956 Paper 38282413 Paper 38276892 Paper 38260384 Paper 38234733 Paper 38224546 Paper 38224146 Paper 38198251 Paper 38191490 Paper 38189981 Paper 38189749 Paper 38150745 Paper 38111006 Paper 38110045 Paper 38089583 Paper 38086495 Paper 38086389 Paper 38043122 Paper 38038976 Paper 38020401 Paper 38018701 Paper 38014176 Paper 38014038 Paper 37994004 Paper 37986935 Paper 37985223 Paper 37984853 Paper 37972072 Paper 37969113 Paper 37955090 Paper 37888107 Paper 37886506 Paper 37855447 Paper 37843849 Paper 37816871 Paper 37808808 Paper 37808092

Abstract

Early structural and functional changes in the brains of individuals at risk for developing dementia of the Alzheimer type (DAT) are not well understood. Typically a diagnosis of DAT is made using neuropsychological performance testing and clinical evaluation. Previous work by our group and others has identified a preclinical phase of DAT that is associated with a constellation of changes in biomarkers including decreased cerebral spinal fluid (CSF) Abeta42 (AP42) levels, increased fibrillar amyloid deposits in the brain as detected by PET (using Pittsburgh B compound (PIB)), and increased atrophy, particularly within the hippocampus. An interaction exists between these biomarkers and risk factors for DAT such as family history and genotype (ie., apolipoprotein E (APOE). The exact sequence of preclinical events, and their effects on neuronal dysfunction that leads to DAT, remain unclear. Recent advancements in MR imaging could provide unique information in this regard. Specifically three techniques- resting state functional connectivity MRI (fcMRI), diffusion tensor imaging (DTI), and arterial spin labeling (ASL) perfusion imaging, could provide sensitive measures of neuronal function (fcMRI), cerebral blood flow (ASL) and white matter integrity (DTI). Repeated longitudinal measures using these neuroimaging techniques could add new information concerning the temporal course associated with the very earliest changes in brain function associated with DAT. This project has 3 aims: Aim 1: Changes in neuronal structure using fcMRI, ASL and DTI in a cross-sectional analysis will be correlated with age, APOE genotype, and biochemical and behavioral biomarkers. Aim 2. Subjects followed longitudinally with repeat fcMRI, ASL, and DTI will provide a temporal profile of the sequence of changes in neuroimaging biomarkers. Aim 3: Associate the rates of change over time in fcMRI, resting cerebral blood flow, and radial diffusivity in DTI measures with cognitive decline (Clinical Core), changes in cortical amyloid load as assessed by PIB (Project 1), changes in CSF biomarkers (Project 2), and neuropsychological measures (Project 3).

View original record on NIH RePORTER →